Armata Pharmaceuticals, Inc.
No SEC Form 4 filings for $ARMP in the last 30 days.
See all $ARMP insider activity →Armata Pharmaceuticals (ARMP) received two U.S. patents for its bacteriophage therapies AP-SA02 and AP-PA02, protecting treatments for Staphylococcus aureus and Pseudomonas infections. The patents extend until 2041 and 2043, respectively. ARMP's portfolio includes 101 issued patents and 60 pending applications. AP-SA02 has FDA designations and a Phase 3 study planned for 2026.
Armata Pharmaceuticals (ARMP) received $3.7M from the U.S. Department of War for Phase 3 development of AP-SA02, a treatment for Staphylococcus aureus bacteremia. This brings total non-dilutive funding to $32.4M. AP-SA02 has FDA designations for fast track and breakthrough therapy.
Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARMP (Armata Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ARMP coverage spans technology, corporate actions and market movers.
The patents extend protection for the company's lead programs, supporting future commercialization and potentially boosting valuation.
The new funding reduces cash‑flow pressure and de‑risks the upcoming Phase 3 trial, potentially supporting the stock ahead of the study start.
The new funding reduces cash‑burn pressure and validates government backing, likely supporting the stock ahead of the upcoming Phase 3 trial.
The new structural biology data reduces perceived development risk and may attract funding or partnership interest.
Positive regulatory milestone likely to boost near‑term price.
AlphAI scores every news story that mentions ARMP with an AI model for sentiment and relevance, and aggregates insider trades from Armata Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Armata Pharmaceuticals (ARMP) received two U.S. patents for its bacteriophage therapies AP-SA02 and AP-PA02, protecting treatments for Staphylococcus aureus and Pseudomonas infections. The patents extend until 2041 and 2043, respectively. ARMP's portfolio includes 101 issued patents and 60 pending applications. AP-SA02 has FDA designations and a Phase 3 study planned for 2026.
2 min readArmata Pharmaceuticals (ARMP) received $3.7M from the U.S. Department of War for Phase 3 development of AP-SA02, a treatment for Staphylococcus aureus bacteremia. This brings total non-dilutive funding to $32.4M. AP-SA02 has FDA designations for fast track and breakthrough therapy.
1 min readArmata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba
1 min readArmata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.
3 min readArmata Pharmaceuticals (ARMP) shares rose 8% after the FDA granted Breakthrough Therapy designation to AP-SA02, a treatment for complicated bacteremia caused by S. aureus. The designation is based on Phase 1b/2a study data showing 100% clinical response in treated patients. The company aims to develop bacteriophage therapeutics for resistant bacterial infections.
1 min readArmata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over availa
2 min readArmata Pharmaceuticals (ARMP) published research in the Journal of Molecular Biology detailing structural insights into Ar-KM, a bacteriophage targeting Pseudomonas aeruginosa. The study could aid in developing next-gen antibacterial therapies. ARMP's AP-PA02 program, using Ar-KM, has completed Phase 2 trials. The company is also expanding structural biology work to other phages. ARMP stock closed at $5.53, up 4.73%, and is down 2.35% in pre-market trading.
1 min readArmata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.
6 min readArmata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo
6 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min read
